The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Ivanov S.V.

Mental Health Research Center

Voronova E.I.

Sechenov First Moscow State Medical University (Sechenov University);
Mental Health Research Center

Depression therapy for somatic diseases

Authors:

Ivanov S.V., Voronova E.I.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2021;121(5‑2): 106‑112

DOI: 10.17116/jnevro2021121052106

Views: 7540

Downloaded: 224

Download PDF (RU)
Contact the author
Table of contents

DEPRESSION THERAPY FOR SOMATIC DISEASES
DEPRESSION THERAPY FOR SOMATIC DISEASES

To cite this article:

Ivanov SV, Voronova EI. Depression therapy for somatic diseases. S.S. Korsakov Journal of Neurology and Psychiatry. 2021;121(5‑2):106‑112. (In Russ.)
https://doi.org/10.17116/jnevro2021121052106

 
Подписка 2025-2 (S.S. Korsakov Journal of Neurology and Psychiatry (special issues))
 
МСФ на ЯМ
Close metadata
Recommended articles:
A perspective on the application of CRISPR/CAS9 genome editing system to study of mole­cular-genetic basis of mental diso­rders. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(3):27-33
Vali­dation of screening method based on EEG analysis for the risk asse­ssment of psychiatric and beha­vioral diso­rders: a pilot study. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(3):88-96
A clinical case of the new-onset bipo­lar affe­ctive diso­rder in the postcovid period. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(3):125-129
Short-term outcomes of mechanical and hand-sewn lapa­roscopic one-anastomosis mini-gastric bypass. Piro­gov Russian Journal of Surgery. 2024;(4):29-37
Pathogenetic basis of modern approaches to the therapy of sleep diso­rders in the clinic of depression. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4):69-74
Features of the clinical picture of affe­ctive diso­rders in women during the meno­pausal transition and early postmenopause. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4):75-79
Therapy of mental diso­rders in patients with hema­tological mali­gnancies. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4):127-136
Targeting NMDAR/AMPAR: a promising pharmacotherapeutic approach for depressive diso­rders. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(5):22-30
Posttraumatic stress diso­rder clinical guidelines and treatment standards: focus on the symptoms of the psychophysiological arousal. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(5):58-68
Asthenia in young patients and possibilities for its correction. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(5):133-137

A review of works devoted to the problem of psychopharmacotherapy of depression in general medical practice is presented. The issues of its comorbidity with somatic and neurological diseases, as well as multimorbidity are discussed. Both direct and side-effects of antidepressants, which are important for effective therapy of not only affective disorders proper, but also the symptoms of the leading pathology, are considered in detail for individual organs and systems. The analysis of the preferred pharmacological classes of antidepressants, which are drugs of first choice, taking into account the somatic condition of the patient, is carried out, and drugs are indicated, the appointment of which is undesirable for the treatment of a patient with a certain disease. The presented results are aimed both at increasing the efficiency of therapy for patients with general medical level of health care, and at increasing the safety of treatment of psychiatric patients with concomitant somatic disorders.

Keywords:

depression
general medicine
psychopharmacotherapy
antidepressants
tolerability
safety

Authors:

Ivanov S.V.

Mental Health Research Center

Voronova E.I.

Sechenov First Moscow State Medical University (Sechenov University);
Mental Health Research Center

Received:

19.04.2021

Accepted:

27.04.2021

List of references:

  1. Smulevich AB, Andryushchenko AV, Beskova DA. Clinical and epidemiological program «SYNTHESIS: the prevalence and structure of mental disorders in general medicine (current issues). In: Mental disorders in clinical practice. M. 2011. (In Russ.).
  2. Rudisch B, Nemeroff CB. Epidemiology of comorbid coronary artery disease and depression. Biol Psychiatry. 2003;54:227-240. 
  3. Anderson RJ, Freedland KE, Clouse RE, Lustman PJ. The prevalence of comorbid depression in adults with diabetes: a meta-analysis. Diabetes Care. 2001;24:1069-1078.
  4. Matcham F, Rayner L, Steer S, Hotopf M. The prevalence of depression in rheumatoid arthritis: a systematic review and meta-analysis. Rheumatology. 2013;52:2136-2148.
  5. Lazarou C, Kout C, Kapsou M, Kaite C. Review of epidemiology of depression and implications for community nursing practice. East Afr J Public Health. 2010;7:246-249. 
  6. Moussavi S, Chatterji S, Verdes E, Tandon A, Patel V, Ustun B. Depression, chronic diseases, and decrements in health: results from the World Health Surveys. Lancet. 2007;370:851-858. 
  7. Read JR, Sharpe L, Modini M, Dear BF. Multimorbidity and depression: A systematic review and meta-analysis. J Affect Disord. 2017;221:36-46. Epub 2017 Jun 14. PMID: 28628766. https://doi.org/10.1016/j.jad.2017.06.009
  8. Frasure-Smith N, Lespérance F, Talajic M. Depression and 18-month prognosis after myocardial infarction. Circulation. 1995;91(4):999-1005. Erratum in: Circulation. 1998;97(7):708. PMID: 7531624. https://doi.org/10.1161/01.cir.91.4.999
  9. Ali S, Stone MA, Peters JL, Davies MJ, Khunti K. The prevalence of co-morbid depression in adults with Type 2 diabetes: a systematic review and meta-analysis. Diabet Med. 2006;23(11):1165-1173. https://doi.org/10.1111/j.1464-5491.2006.01943.x
  10. Hazuda HP, Gaussoin SA, Wing RR, Yanovski SZ, Johnson KC, Coday M, Wadden TA, Horton ES, Van Dorsten B, Knowler WC.; Look AHEAD Research Group. Long-term Association of Depression Symptoms and Antidepressant Medication Use With Incident Cardiovascular Events in the Look AHEAD (Action for Health in Diabetes) Clinical Trial of Weight Loss in Type 2 Diabetes. Diabetes Care. 2019;42(5):910-918. Epub 2019 Mar 4.  https://doi.org/10.2337/dc18-0575
  11. Nagler EV, Webster AC, Vanholder R, Zoccali C. Antidepressants for depression in stage 3—5 chronic kidney disease: a systematic review of pharmacokinetics, efficacy and safety with recommendations by European Renal Best Practice (ERBP). Nephrol Dial Transplant. 2012;27(10):3736-3745. Epub 2012 Aug 1.  https://doi.org/10.1093/ndt/gfs295
  12. Brouwers C, Christensen SB, Damen NL, Denollet J, Torp-Pedersen C, Gislason GH, Pedersen SS. Antidepressant use and risk for mortality in 121,252 heart failure patients with or without a diagnosis of clinical depression. Int J Cardiol. 2016;203:867-873. 
  13. Teply RM, Packard KA, White ND, Hilleman D, DiNicolantonio JJ. Treatment of Depression in Patients with Concomitant Cardiac Disease. Prog Cardiovasc Dis. 2016;58(5):514-528.  https://doi.org/10.1016/j.pcad.2015.11.003
  14. Almeida OP, Ford AH, Hankey GJ, Golledge J, Yeap BB, Flicker L. Depression, antidepressants and the risk of cardiovascular events and death in older men. Maturitas. 2019;128:4-9. Epub 2019 Jun 28. PMID: 315618. https://doi.org/10.1016/j.maturitas.2019.06.009
  15. Psychosomatic disorders. A guide for practitioners. Under ed. Academician Smulevich A.B. M.: Medpress-Inform; 2019. (In Russ.).
  16. Samushia MA, Mustafina EA. Stimuloton (sertraline) in the therapy of depressive disorders in patients with cancer. Mental Disorders in General Medicine. 2007;2:30-34. (In Russ.).
  17. Samushia MA. Fevarin (fluvoxamine) in the therapy of anxiety-depressive nosogenic reactions in patients with cancer. Mental Disorders in General Medicine. 2008;1:33-37. (In Russ.).
  18. Samushia MA, Myasnikova LK. Valdoxan (agomelatin) in the therapy of depressive disorders in patients with oncological diseases of the organs of the female reproductive system. Mental Disorders in General Medicine. 2012;3:21-25. (In Russ.).
  19. Ivanov SV, Volel BA, Syrkina EA, Ternovaya ES, Troshina DV, Grubova MV, Tolkacheva IA, Rozhkov AN, Simonov AN. Retrospective archival study on assessing the safety of the use of modern antidepressants in cardiac practice. Therapeutic Archive. 2017;89:12:34-42. (In Russ.).
  20. Bangalore S, Shah R, Pappadopulos E, Deshpande A, Shelbaya R, Prieto J, Stephens R. Cardiovascular hazards of insufficient treatment of depression among patients with known cardiovascular disease: a propensity score adjusted analysis. Eur Heart J Qual Care Clin Outcomes. 2018;4(4):258-266.  https://doi.org/10.1093/ehjqcco/qcy023
  21. Glassman AH, O’Connor CM, Califf RM, Swedberg K, Schwartz P, Bigger ThJr, Krishnan RR, van Zyl LT, Swenson JR, Finkel MS, Landau C, Shapiro PA, Pepine CJ, Mardekian J, Harrison WM. Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA. 2002;288:701-709. 
  22. Poluzzi E, Raschi E, Moretti U, De Ponti F. Drug-induced torsades de pointes: data mining of the public version of the FDA Adverse Event Reporting System (AERS). Pharmacoepidemiol Drug Saf. 2009;18:512-518. 
  23. Astrom-Lilja C, Odeberg JM, Ekman E, Hagg S. Drug-induced torsades de pointes: a review of the Swedish pharmacovigilance database. Pharmacoepidemiology and Drug Safety. 2008;17:587-592. 
  24. Wenzel-Seifert K, Wittmann M, Haen E. Torsade de Pointes episodes under treatment with selective serotonin reuptake inhibitors. Pharmacopsychiatry. 2010;43:279-281. 
  25. Castro VM, Clements CC, Murphy SN, Vivian GS, Fava M, Weilburg J, Erb JL, Churchill SE, Kohane IS, Iosifescu DV, Smoller JW, Perlis R. QT interval and antidepressant use: a cross sectional study of electronic health records. BMJ. 2013;346:f288. https://doi.org/10.1136/bmj.f288
  26. Mbaya P, Alam F, Ashim S, Bennett D. Cardiovascular effects of high dose venlafaxine XL in patients with major depressive disorder. Hum Psychopharmacol. 2007;22:129-133. 
  27. Letsas K, Korantzopoulos P, Pappas L, Evangelou D, Efremidis M, Kardaras F. QT interval prolongation associated with venlafaxine administration. Int J Cardiol. 2006;109(1):116-117.  https://doi.org/10.1016/j.ijcard.2005.03.065
  28. Wernicke J, Lledó A, Raskin J, Lledó A, Kajdasz D. An evaluation of the cardiovascular safety profile of duloxetine: findings from 42 placebo-controlled studies. Drug Saf. 2007;30(5):437-455.  https://doi.org/10.2165/00002018-200730050-00007
  29. Olié JP, Gourion D, Montagne A, Rostin M, Poirier M-F. Milnacipran and venlafaxine at flexible doses (up to 200 mg/day) in the outpatient treatment of adults with moderate-to-severe major depressive disorder: a 24-week randomized, double-blind exploratory study. Neuropsychiatr Dis Treat. 2010;6:71-79. 
  30. Kamijima K, Hashimoto S, Nagayoshi E, Koyama T. Double-blind, comparative study of milnacipran and paroxetine in Japanese patients with major depression. Neuropsychiatr Dis Treat. 2013;9:555-565.  https://doi.org/10.2147/NDT.S42915
  31. Van den Brink RHS, Van Melle JP, Honig A, Schene AH, Crijns HJGM, Lambert F, Ormel J. Treatment of depression after myocardial infarction and the effects on cardiac prognosis and quality of life: rationale and outline of the myocardial infarction and depression-intervention trial (MIND-IT). Am Heart J. 2002;144:219-225. 
  32. Goodnick PJ, Jerry J, Parra F. Psychotropic drugs and the ECG: focus on the QTc interval. Expert Opin Pharmacother. 2002;3:479-498. 
  33. Hla KK, Boyd O. Mianserin and complete heart block. Hum Toxicol. 1987;6(5):401-402. 
  34. Haefeli WE, Schoenenberger RA, Scholer A. Recurrent ventricular fibrillation in mianserin intoxication. BMJ. 1991;302(6773):415-416. 
  35. Newman B, Crome P. The clinical toxicology of mianserin hydrochloride. Vet Hum Toxicol. 1979;21(suppl):60-62. 
  36. Fagiolini A, Comandini A, Catena Dell’Osso M, Kasper S. Rediscovering trazodone for the treatment of major depressive disorder. CNS Drugs. 2012;26:1033-1049. https://doi.org/10.1007/s40263-012-0010-5
  37. Raysky VA. Psychotropic drugs in the clinic of internal diseases. M. 1988. (In Russ.).
  38. Fiedler VB, Buchheim S, Nitz RE, Scholtholt J. Haemodynamic effects of pirlindole, a new tetracyclic antidepressant agent. Arzneimittelforschung. 1983;33(2):244-250. 
  39. Zaitsev VP, Koltsova TI. Use of tricyclic antidepressants in coronary heart disease. Klin med. 1980;6:30-35. (In Russ.).
  40. Kennedy SH, Rizvi SJ. Agomelatine in the treatment of major depressive disorder: potential for clinical effectiveness. CNS Drugs. 2010;24(6):479-499. 
  41. Donazzolo Y, Latreille M, Caillaud M-A, Mocaer E, Seguin L. Evaluation of the Effects of Therapeutic and Supratherapeutic Doses of Agomelatine on the QT/QTc Interval: A Phase I, Randomized, Double-blind, Placebo-controlled and Positive-controlled, Crossover Thorough QT/QTc Study Conducted in Healthy Volunteers. J Cardiovasc Pharmacol. 2014;64:440-451. 
  42. Medvedev VE, Epifanov AV. Innovative method of therapy of depression in patients with coronary heart disease. Review of Psychiatry and Med Psychology. 2010;3:46-50. (In Russ.).
  43. Statsenko ME, Shilina NN, Turkina SV. Effectiveness of Valdoxan use in the recovery period of myocardial infarction in patients with type 2 diabetes mellitus and anxiety-depressive disorders. Psychiatry and Psychopharmacotherapy. 2012;14(6):8-13. (In Russ.).
  44. Andrade C, Sandarsh S, Chethan KB, Nagesh KS. Serotonin reuptake inhibitor antidepressants and abnormal bleeding: a review for clinicians and a reconsideration of mechanisms. J Clin Psychiatry. 2010;71(12):1565-1575. https://doi.org/10.4088/JCP.09r05786blu
  45. Ramasubbu R. Cerebrovascular effects of selective serotonin reuptake inhibitors: a systematic review. J Clin Psychiatry. 2004;65(12):1642-1653.
  46. Kharofa J, Sekar P, Haverbusch M, et al. Selective serotonin reuptake inhibitors and risk of hemorrhagic stroke. Stroke. 2007;38(11):3049-3051.
  47. van Walraven C, Mamdani MM, Wells PS, Williams JI. Inhibition of serotonin reuptake by antidepressants and upper gastrointestinal bleeding in elderly patients: retrospective cohort study. BMJ. 2001;22;323(7314):655-658. 
  48. Castro VM, Gallagher PJ, Clements CC, Patience J, Murphy S. Incident user cohort study of risk for gastrointestinal bleed and stroke in individuals with major depressive disorder treated with antidepressants. BMJ Open. 2012;2(2):e000544. https://doi.org/10.1136/bmjopen-2011-000544
  49. Mosolov SN. Reference Manual on psychotropic and antiepileptic drugs allowed for use in Russia. M. 2002. (In Russ.).
  50. Dalton SO, Johansen C, Mellemkjaer L, Nørgård B, Sørensen HT, Olsen JH. Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: a population-based cohort study. Arch Intern Med. 2003;13;163(1):59-64. 
  51. Gershon MD. 5-hydroxytryptamine (serotonin) in the gastrointestinal tract. Curr Opin Endocrinol Diabetes Obes. 2013;20:14-21. 
  52. Janssen P, Vos R, Tack J. The influence of citalopram on interdigestive gastrointestinal motility in man. Aliment Pharmacol Ther. 2010;32:289-295. 
  53. Browning KN. Role of central vagal 5-HT3 receptors in gastrointestinal physiology and pathophysiology. Front Neurosci. 2015;9:413. 
  54. Correll CU, Detraux J, De Lepeleire J, De Hert M. Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder. World Psychiatry. 2015;14(2):119-136. 
  55. Wang YP, Chen YT, Tsai CF, et al. Short-term use of serotonin reuptake inhibitors and risk of upper gastrointestinal bleeding. Am J Psychiatry. 2014;171:54-61.  https://doi.org/10.1176/appi.ajp.2013.12111467
  56. Gartlehner G, Hansen RA, Reichenpfader U, Li SY, Luo JC, Wang SJ, Tang CH, Liu CJ, Lin HC, Lee FY, Chang FY, Lu CL. Drug Class Review: Second-Generation Antidepressants: Final Update 5 Report. Drug Class Reviews. Portland, Oregon Health and Science University. 2011.
  57. Farah A. Interferon-induced depression treated with citalopram. J Clin Psychiatry. 2002;63:166-167. 
  58. Hauser P, Khosla J, Aurora H, Laurin J, Kling MA, Hill J, Gulati M, Thornton AJ, Schultz RL, Valentine AD, Meyers CA, Howell CD. A prospective study of the incidence and open-label treatment of interferon-induced major depressive disorder in patients with hepatitis C. Mol Psychiatry. 2002;7(9):942-947. 
  59. Kraus MR, Schafer A. Paroxetine for the prevention of depression induced by interferon alfa. N Engl J Med. 2001;345:5:375-376. 
  60. Levenson JL, Fallon HJ. Fluoxetine treatment of depression caused by interferon-alpha. Am J Gastroenterol. 1993;88(5):760-761. 
  61. Sammut S, Bethus I, Goodall G, Muscat R. Antidepressant reversal of interferon-alpha-induced anhedonia. Physiol Behav. 2002;75(5):765-772. 
  62. Schramm TM, Lawford BR, Macdonald GA. Sertraline treatment of interferon-alfa-induced depressive disorder. Med J Aust. 2000;173(7):359-361. 
  63. Billioti de Gage S, Collin C, Le-Tri Th, Pariente A, Bégaud B, Verdoux H, Dray-Spira R. Antidepressants and Hepatotoxicity: A Cohort Study among 5 Million Individuals Registered in the French National Health Insurance Database. CNS Drugs. 2018; 2(7):673-684.  https://doi.org/10.1007/s40263-018-0537-1
  64. Jacobson S. Psychopharmacology: prescribing for patients with hepatic or renal disfunction. Psychiatric Times (November). 2002;65-69. 
  65. Robinson MJ, Owen JA. Psychopharmacology. In: Levinson J, editor. The American Psychiatric Publishing textbook of psychosomatic medicine. Washington (DC): American Psychiatric Publishing Inc; 2005.
  66. Berken GH, Weinstein DO, Stern WC. Weight gain. A side-effect of tricyclic antidepressants. J Affect Disord. 1984;7(2):133-138. 
  67. Serretti A, Mandelli L. Antidepressants and body weight: a comprehensive review and meta-analysis. J Clin Psychiatry. 2010;71:1259-1272.
  68. Sussman N, Ginsberg DL. Weight effects of nefazodone, bupropion, mirtazapine, and venlafaxine: a review of available evidence. Primary Psychiatry. 2000;7:33-48. 
  69. Lee SH, Paz-Filho G, Mastronardi C, Licinio J, Wong ML. Is increased antidepressant exposure a contributory factor to the obesity pandemic? Transl Psychiatry. 2016;6.  https://doi.org/10.1038/TP.2016.25
  70. Michelson D, Amsterdam JD, Quitkin FM. Changes in weight during a 1-year trial of fluoxetine. Am J Psychiatry. 1999;156:1170-1176.
  71. Drieling T, Biedermann NC, Schärer LO, Strobl1 N, Langosch JM. Psychotropic drug-induced change of weight: a review. Fortschr Neurol Psychiatr. 2007;75(2):65-80.  https://doi.org/10.1055/s-2005-919109
  72. Patten SB, Williams JV, Lavorato DH, Brown L, McLaren L, Eliasziw M. Major depression, antidepressant medication and the risk of obesity. Psychother Psychosom. 2009;78:182-186. 
  73. Bhattacharjee S, Bhattacharya R, Kelley GA, Sambamoorthi U. Antidepressant use and new-onset diabetes: a systematic review and meta-analysis. Diabetes Metab Res Rev. 2013;29:273-284. 
  74. Roopan S, Larsen ER. Use of antidepressants in patients with depression and comorbid diabetes mellitus: a systematic review. Acta Neuropsychiatr. 2017;29(3):127-139.  https://doi.org/10.1017/neu.2016.54
  75. Griebeler ML, Morey-Vargas OL, Brito JP, Tsapas A, Wang Z, Leon B, Phung OJ, Montori VM, Murad M. Pharmacologic interventions for painful diabetic neuropathy: An umbrella systematic review and comparative effectiveness network meta-analysis. Ann Intern Med. 2014;161(9):639-649.  https://doi.org/10.7326/M14-0511
  76. Gregg LP, Hedayati SS. Pharmacologic and psychological interventions for depression treatment in patients with kidney disease. Curr Opin Nephrol Hypertens. 2020;29(5):457-464.  https://doi.org/10.1097/MNH.0000000000000629
  77. Iwagami M, Tomlinson LA, Mansfield KE, Douglas IJ, Smeeth L, Nitsch D. Gastrointestinal bleeding risk of selective serotonin reuptake inhibitors by level of kidney function: A population-based cohort study. Br J Clin Pharmacol. 2018;84(9):2142-2151. https://doi.org/10.1111/bcp.13660
  78. Ostuzzi G, Matcham F, Dauchy S, Barbui C, Hotopf M. Antidepressants for the treatment of depression in people with cancer. Cochrane Database Syst Rev. 2018;4(4):CD011006..CD011006.pub3. https://doi.org/10.1002/14651858
  79. Musselman DL, Lawson DH, Gumnick JF, Manatunga AK, Penna S, Goodkin RS, Greiner K, Nemeroff CB, Miller AH. Paroxetine for the prevention of depression induced by high-dose interferon alfa. N Engl J Med. 2001;344:961-966.  https://doi.org/10.1080/14656566.2017.1334765
  80. Capuron L, Gumnick JF, Musselman DL, Lawson DH, Reemsnyder A, Nemeroff CB, Miller AH. Neurobehavioral effects of interferon-alpha in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions. Neuropsychopharmacology. 2002;26:643-652. 
  81. Loprinzi CL, Sloan JA, Perez EA. Phase III evaluation of fluoxetine for treatment of hot flashes. Journal of Clinical Oncology. 2002;6:1578-1583. https://doi.org/10.1200/JCO.20.6.1578
  82. Kimmick GG, Peterson BL, Kornblith AB, Mandelblat J, Johnson JL, Wheeler J, Heinze R, Cohen HJ, Muss HB. Improving Accrual of Older Persons to Cancer Treatment Trials: A Randomized Trial Comparing an Educational Intervention with standard information: CALGB 360001. Journal of Clinical Oncology. 2004;23:2201-2207. https://doi.org/10.1200/JCO.2005.01.222
  83. Spina E, Santoro V, D’Arrigohang C. Clinically relevant pharmacokinetic drug interactions with second-generation antidepressants: an update. Clin Ther. 2008;30(7):1206-1227. https://doi.org/10.1016/s0149-2918(08)80047-1

Close metadata

Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.